Express Pharma

DECEMBER 9, 2024

ISB2001 Phase 1 Dose Escalation Study Design The Phase 1, first-in-human, open-label study is evaluating the safety and anti-myeloma activity of ISB2001 in patients with RRMM. No immune cell-associated neurotoxicity syndrome (ICANS) was observed. The median duration of CRS was 2 days (range: 18).

Immunity 52

Immunity Immunization Hospitals Labelling 52

Pharmacy Friday Pearls

MARCH 9, 2022

Crotalidae Polyvalent Immune FAB (Ovine). Crotalidae Immune F(ab’)2 (Equine). Patients can develop delayed or recurrent hematologic symptoms up to a week after treatment cessation, especially following a severe envenomation. Pharmacology. in the treatment group vs 7.4 in the control group (95% CI 0.1 – 2.3; 2020;77(3):175-187.

Immunity 40

Immunity Immunization Packaging Labelling 40

The Thyroid Pharmacist

JULY 29, 2022

Breathing in pollutants is inflammatory, and triggers an immune response as the body tries to process out the toxins. Perhaps more concerning, of the 133 different VOCs found across all tested products, only one, ethanol, was actually listed on any label! (13, But formaldehyde has been labeled as a known human carcinogen by the U.S.

Health and Personal Care Stores 52

Health and Personal Care Stores Compounding Immunity Immunization 52

PharmaShots

FEBRUARY 21, 2023

Nordic is advancing the development of CD37-targeted therapies for hematological cancers and immune diseases. FAP-2286 (labeled with lutetium-177), a peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting fibroblast activation protein (FAP), is the company’s lead asset amongst radiopharma products.

Dosage 56

Dosage Labelling Immunity Immunization 56